Vasopeptidase Inhibitors: Boosting Protective Peptides While Blocking Harmful Ones for Heart Disease | Research

The takeaway

Vasopeptidase inhibitors represent a new paradigm — simultaneously enhancing protective natriuretic/bradykinin peptides while blocking harmful angiotensin, with superior blood pressure and heart failure benefits over single-target drugs.

Boost + block
One drug simultaneously increases protective natriuretic peptides/bradykinin AND decreases harmful angiotensin II — dual-action cardiovascular therapy

What the researchers found

Vasopeptidase inhibitors simultaneously enhance protective natriuretic peptides/bradykinin and block harmful angiotensin II, showing superior cardiovascular benefits over ACE inhibitors alone, despite angioedema risk as a limitation.

Why it matters

This dual approach to cardiovascular therapy — boost protection AND block harm simultaneously — has proven transformative, evolving into the sacubitril/valsartan (Entresto) concept now saving lives worldwide.

How the study worked

Comprehensive review of vasopeptidase inhibitor pharmacology, clinical trial data, and therapeutic potential for hypertension and heart failure.

What this study cannot tell us

First-generation vasopeptidase inhibitors (omapatrilat) had angioedema risk. The review preceded sacubitril/valsartan's success in avoiding this limitation.

How to read the evidence

Moderate evidence from a review of preclinical and clinical data demonstrating consistent cardiovascular benefits of dual inhibition.

When this study was published

Published in 2001. This concept evolved into sacubitril/valsartan (Entresto), which avoided angioedema by separating the inhibitors, and is now standard heart failure therapy.

The bigger picture

The evolution from single-target ACE inhibitors to dual-target vasopeptidase inhibitors to the refined sacubitril/valsartan represents a paradigm shift in cardiovascular medicine toward multi-target peptide modulation.

Questions still open

Can the angioedema risk be eliminated while maintaining dual benefits?
Should vasopeptidase inhibition be used in all heart failure stages?
Could triple peptidase inhibition provide additional benefits?

Common questions

What is vasopeptidase inhibition?

It's simultaneously blocking two enzymes: one that destroys protective heart peptides (NEP) and one that creates harmful angiotensin (ACE). The result is more natural protection and less harm — from a single drug.

Is this the same as Entresto?

Entresto (sacubitril/valsartan) is the refined descendant of vasopeptidase inhibitors. It combines a neprilysin inhibitor with an ARB instead of an ACE inhibitor, avoiding the angioedema risk of earlier drugs while keeping the dual benefits.

Read the original research

Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?

Circulation, 104(15), 1856-62

View on PubMed ↗

Citation

Corti, R; Burnett, J C; Rouleau, J L; Ruschitzka, F; Lüscher, T F. (2001). Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?. Circulation, 104(15), 1856-62.